PreveCeutical Provides Update on Management Cease Trade Order
PreveCeutical Provides Update on Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is providing an update with respect to the Management Cease Trade Order ("MCTO") issued by the British Columbia Securities Commission (the "BCSC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), effective as of May 2, 2024, and as previously announced by the Company.
不列顛哥倫比亞省溫哥華--(Newsfile Corp.-2024 年 5 月 16 日)- preveCeutical Medical Inc (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the”公司“或”preveCeutical“) 正在提供有關《管理層停止交易令》的最新信息 (”MCTO“)由不列顛哥倫比亞省證券委員會發行(”BCSC“) 根據國家政策 12-203- 管理層停止交易訂單 (”NP 12-203“),自2024年5月2日起生效,並由公司先前宣佈。
The MCTO was issued by the BCSC in connection with the delay by the Company in filing its audited annual financial statements and accompanying management's discussion and analysis, with related CEO and CFO certificates, for the financial year ended December 31, 2023 (collectively, the "Annual Filings") by the deadline of April 29, 2024, as required under applicable Canadian securities laws.
MCTO由BCSC發佈,原因是該公司延遲提交截至2023年12月31日的財政年度的經審計的年度財務報表和隨附的管理層討論和分析以及相關的首席執行官和首席財務官證書(統稱爲”年度申報“)根據適用的加拿大證券法的要求,在2024年4月29日的最後期限之前。
The Company was unable to file its Annual Filings within the required time due to a lack of funds, which prevented the Company from engaging its auditors and completing its audit in a timely manner. The Company has since engaged Smythe LLP and expects to file the Annual Filings as soon as they are available, but in any event no later than June 28, 2024. The Company will issue a news release once the Annual Filings have been filed.
由於缺乏資金,公司無法在規定的時間內提交年度申報,這使公司無法聘請核數師和及時完成審計。此後,該公司聘請了Smythe LLP,並預計將在年度申報發佈後儘快提交,但無論如何都不遲於2024年6月28日。提交年度申報後,公司將發佈新聞稿。
The Company is providing this status update in accordance with NP 12-203. Until the Company files the Annual Filings, it will comply with the alternative information guidelines set out in NP 12-203, including the issuance of bi-weekly default status reports in the form of news releases.
該公司根據NP 12-203提供此狀態更新。在公司提交年度申報之前,它將遵守NP 12-203中規定的替代信息指南,包括每兩週以新聞稿的形式發佈違約狀態報告。
The Company also anticipates completing a private placement for gross proceeds of up to $250,000 (the "Proposed Private Placement") in the near future, and expects to use the proceeds of the Proposed Private Placement for working capital purposes, including payment of audit related fees. The Company will provide further details on the Proposed Private Placement in a subsequent news release.
該公司還預計將完成私募配售,總收益高達25萬美元(”擬議的私募配售“)在不久的將來,並預計將擬議私募的收益用於營運資金用途,包括支付審計相關費用。該公司將在隨後的新聞稿中提供有關擬議私募的更多細節。
During the MCTO, the general investing public will continue to be able to trade in the Company's common shares (the "Shares") listed on the Canadian Securities Exchange. However, the Company's CEO, CFO and such other directors, officers and persons as determined by the applicable regulatory authorities will not be able to trade in the Shares, nor will the Company be able to, directly or indirectly, issue securities to or acquire securities from an insider or employee of the Company except in accordance with legally binding obligations to do so existing as of April 29, 2024, being the date of the Company's continuous disclosure default.
在MCTO 期間,普通投資公衆將繼續能夠交易公司的普通股(”股份“)在加拿大證券交易所上市。但是,公司的首席執行官、首席財務官以及相關監管機構確定的其他董事、高級管理人員和人員將無法交易股票,也無法直接或間接向公司內部人士或員工發行證券或從公司內部人士或員工那裏收購證券,除非根據截至2024年4月29日,即公司持續披露違約之日存在的具有法律約束力的義務。
The Company is not subject to any insolvency proceedings. If the Company provides any information to any of its creditors during the period in which it is in default of filing the Annual Filings, the Company confirms that it will also file material change reports on SEDAR+ containing such information. The Company confirms as of the date of this news release that there has been no material change in the information contained in the default announcement issued on May 2, 2024, and there is no other material information concerning the affairs of the Company that has not been generally disclosed.
公司不受任何破產程序的約束。如果公司在未提交年度申報期間向任何債權人提供任何信息,則公司確認還將在SEDAR+上提交包含此類信息的重大變更報告。公司確認,截至本新聞稿發佈之日,2024年5月2日發佈的默認公告中包含的信息沒有實質性變化,也沒有其他未普遍披露的有關公司事務的重大信息。
About PreveCeutical
關於 PreveUtical
PreveCeutical is a health sciences company focused on developing innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
preveCeutical是一家健康科學公司,致力於利用有機和自然相同的產品爲預防和治療療法開發創新的選擇。該公司的目標是成爲預防健康科學領域的領導者。
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.
隨着三項研究計劃的完成,該公司正在積極致力於其產品的開發、臨床試驗和商業化;並已提交了多項臨時專利申請,以保護知識產權免受其研究計劃的影響。
For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook.
有關PreveCeutical的更多信息,請訪問我們的網站或在推特和臉書上關注我們。
On behalf of the Board of Directors of PreveCeutical
代表 PreveCeutical 董事會
Stephen Van Deventer, Chairman, Chief Executive Officer and interim Chief Financial Officer
Stephen Van Deventer,董事長、首席執行官兼臨時首席財務官
For further information, please contact:
欲了解更多信息,請聯繫:
Stephen Van Deventer: +1 604 306 9669
Stephen Van Deventer:+1 604 306 9669
Or Investor Relations ir@preveceutical.com
或者投資者關係 ir@preveceutical.com
Forward-Looking Statements
前瞻性陳述
Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified using forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management's expectations and intentions with respect to, among other things: the Company's Proposed Private Placement; the Company's plans relating to the development, clinical trials and commercialization of its products; management expectations that it will be able to file the Annual Filings within the time period described herein.
關於前瞻性陳述的警示說明:本新聞稿包括某些陳述和信息,這些陳述和信息可能構成適用的加拿大證券法所指的前瞻性信息。前瞻性陳述與未來事件或未來業績有關,反映了公司管理層對未來事件的期望或信念。通常,可以使用諸如 “打算” 或 “預期” 之類的前瞻性術語來識別前瞻性陳述和信息,或者某些行爲、事件或結果 “可能”、“應該”、“將” 或 “發生” 的此類詞語和短語或陳述的變體。這些信息和這些陳述(此處稱爲 “前瞻性陳述”)不是歷史事實,是截至本新聞發佈之日作出的,包括但不限於關於未來計劃、估計和預測討論的聲明,以及關於管理層對以下方面的預期和意圖的陳述:公司擬議的私募配售;公司與產品開發、臨床試驗和商業化有關的計劃;管理層對其的期望將能夠提交在本文所述的時間段內提交年度申報。
These forward‐looking statements involve numerous risks and uncertainties and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the Company being unable to execute its business plans as intended; the Company being unable to file the Annual Filings in the proposed timeframe; the Company being unable to complete the Proposed Private Placement; recent market volatility; and the state of the financial markets for the Company's securities.
這些前瞻性陳述涉及許多風險和不確定性,實際結果可能與任何前瞻性陳述中建議的結果存在重大差異。除其他外,這些風險和不確定性包括:公司無法按預期執行其業務計劃;公司無法在擬議的時間範圍內提交年度申報;公司無法完成擬議的私募配售;最近的市場波動;以及公司證券的金融市場狀況。
In making the forward-looking statements in this news release, the Company has applied certain material assumptions, including without limitation, that: the Company will be able to execute its business plans as intended; the Company will be able to file the Annual Filings in the proposed time frame.
在本新聞稿中發表前瞻性陳述時,公司運用了某些重要假設,包括但不限於:公司將能夠按預期執行其業務計劃;公司將能夠在擬議的時間範圍內提交年度申報。
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
儘管公司管理層試圖確定可能導致實際業績與前瞻性陳述或前瞻性信息中包含的結果存在重大差異的重要因素,但可能還有其他因素導致業績不如預期、估計或預期。無法保證此類陳述會被證明是準確的,因爲實際結果和未來事件可能與此類聲明中的預期存在重大差異。因此,讀者不應過分依賴前瞻性陳述和前瞻性信息。提醒讀者,依賴此類信息可能不適合用於其他目的。除非符合適用的證券法,否則公司不承諾更新此處以引用方式納入的任何前瞻性陳述、前瞻性信息或財務展望。我們尋求安全港。